Nalaganje...
Mechanisms of resistance to KRAS(G12C)-targeted therapy
KRAS mutations are among the most common drivers of human carcinogenesis, and are associated with poor prognosis and an aggressive disease course. With the advent of KRAS(G12C) inhibitors, the RAS protein is now targetable, with such inhibitors showing marked clinical responses across multiple tumor...
Shranjeno v:
| izdano v: | Cancer Discov |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8178176/ https://ncbi.nlm.nih.gov/pubmed/33820777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1616 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|